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Because of the failure of single modality approaches, combination therapy for cancer treatment is a promising alternative.
Sphingolipid analogs, with or without anticancer drugs, can improve tumor response. C16-pyridinium ceramide analog LCL30,
was used in combination with photodynamic therapy (PDT), an anticancer treatment modality, to test the hypothesis that the
combined treatment will trigger changes in the sphingolipid proﬁle and promote cell death. Using SCCVII mouse squamous
carcinoma cells, and the silicone phthalocyanine Pc 4 for PDT, we showed that combining PDT with LCL30 (PDT/LCL30) was
more eﬀective than individual treatments in raising global ceramide levels, as well as in reducing dihydrosphingosine levels.
Unlike LCL30, PDT, alone or combined, increased total dihydroceramide levels. Sphingosine levels were unaﬀected by LCL30,
but were abolished after PDT or the combination. LCL30-triggered rise in sphingosine-1-phosphate was reversed post-PDT or the
combination. DEVDase activation was evoked after PDT or LCL30, and was promoted post- PDT/LCL30. Neither mitochondrial
depolarization nor apoptosis were observed after any of the treatments. Notably, treatment with the combination resulted in
augmented overall cell killing. Our data demonstrate that treatment with PDT/LCL30 leads to enhanced global ceramide levels
and DEVDase activation in the absence of apoptosis, and promotion of total cell killing.
1.Introduction
Sphingolipids (SLs) are structural components of cell
membranes, as well as important players in a variety of
biological functions [1]. Ceramide and sphingosine have
been associated with proapoptotic and tumor-suppressor
functions, whereas sphingosine-1-phosphate (S1P) appears
to have prosurvival and tumor-promoting eﬀects [2, 3].
Targeting SLs has been used for new anticancer drug
design [4, 5]. Exposure of chemoresistant MCF-7 cells to
short-chain ceramide analogs, for example, 4,6-dienece-
ramide, leads to the accumulation of endogenous ceramide,
apoptosis, and inhibition of clonogenic survival [6–8].
Cationic ceramide conjugates with pyridinium salts (CCPS
analogs) were synthesized that target mitochondria and with
improved physicochemical properties [9]. Mitochondrial
targeting is important for cancer treatment because cancer
cells tend to have mitochondria with more negative mito-
chondrial membrane potential [10]. These novel ceramide
analogs (C2-C16 CCPS) are potent anticancer agents, alone
or in combination with standard chemotherapy [9, 11–14].
Exposure of MCF-7 cells to the short-chain homolog LCL292 Journal of Lipids
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Figure 1: De novo ceramide metabolism.
(C6-CCPS) targets mitochondria to trigger cell killing [15].
Similarly, LCL124, the (2S,3S) isomer of LCL29, alone or
in combination with gemcitabine, had potent anticancer
activity against human head and neck squamous cell carci-
nomas in vitro and in vivo [12]. Long-chain ceramide analog
LCL30 (C16-CCPS) was shown to target mitochondria and
to trigger cell death in SW403 human colon carcinoma cells
[13]. In addition, LCL30 was an eﬀective anticancer agent in
a colorectal cancer mouse model [14].
Photodynamic therapy (PDT) is a treatment modality
for eﬀective abolishment of malignancies including head and
neck cancers. In PDT, a light-absorbing agent (photosen-
sitizer) is activated by highly-focused laser light to trigger
oxidative stress and destruction of a cellular target [16, 17].
PDT alone, however, can be ineﬀective with some tumors
[18, 19]. To overcome ineﬃciency of PDT itself to eradicate
tumors, combined treatments become a necessary option.
UsingLCL29[9,20]incombinationwithPhotofrin-PDT,we
have shown moderately improved in vivo response of mouse
SCCVII squamous carcinomas [21].
Here, we used for the ﬁrst time LCL30 in combina-
tion with PDT to determine their eﬀects on endogenous
SLs, apoptosis, and clonogenic survival in SCCVII mouse
squamous carcinoma cells (SCCVII cells). The model was
chosen in order to use the results of this study in our
future in vivo work in syngeneic mouse SCCVII squamous
carcinomas, a recognized mouse model for human head
and neck cancers [22], since intact immune system is a
key to PDT therapeutic success [16, 17]. For PDT, silicon
phthalocyanine Pc 4, a photosensitizer with physicochemical
properties superior to Photofrin [23, 24], was chosen for
these investigations. SLs that were analyzed by mass spec-
trometry (MS) are shown in Figure 1 as part of, or relative
to the de novo ceramide pathway. Others [25–30]a n dw e
[21, 31–35] have shown that the de novo ceramide pathway
modulates response to anticancer drugs, including PDT. For
example, we have shown in Jurkat cells that silencing of
ceramide-utilizing enzyme sphingomyelin synthase leads to
enhanced ceramide and dihydroceramide accumulationwith
concomitant promotion of apoptosis [32]. Combining PDT
with the anticancer LCL30 is expected to promote tumor
response to PDT and, therefore, improve clinical PDT.
2.MaterialsandMethods
2.1. Materials. D-erythro-2-N-[16
 -(1  -pyridinium)-hexa-
decanoyl]-sphingosine bromide (LCL30) was synthesized in
the Lipidomics Shared Resource of the Medical University
of South Carolina [9]. The phthalocyanine photosensitizer
Pc 4, HOSiPcOSi(CH3)2(CH2)3N(CH3)2, was supplied by
Dr. Malcolm E. Kenney (Department of Chemistry, Case
Western Reserve University). RPMI medium and serum were
from Invitrogen and Hyclone, respectively.
2.2. Cell Culture and Treatments. SCCVII cells were grown
in RPMI medium (Invitrogen) containing 10% fetal bovine
serum (Hyclone) 100units/mL penicillin and 100μg/mL
streptomycin. Cells were maintained at 37◦Ci na5 %C O 2
atmosphere and were treated in the growth medium. For
PDT experiments, after overnight incubation with Pc 4 at
37◦C, cells were irradiated with red light (2 milliwatts/cm2;
λmax ∼ 670nm) using a light-emitting diode array light
source (EFOS) at the ﬂuence of 200mJ/cm2 at room
temperature. Following PDT, cells were incubated at 37◦C
for 2 hours. For the combination, LCL30 (1μM) was added
to Pc 4-pretreated cell cultures 2 hours prior to irradiation.
For cells treated with LCL30 alone, the incubation time was
4 hours. Following treatments, cells were collected on ice and
processed for various analyses. For MS analysis, cells were
washed twice with cold phosphate-buﬀered saline (PBS),
resuspended in the mixture of ethyl acetate/methanol (1:1,
v/v), dried under nitrogen, and shipped overnight on dry
ice to the Lipidomics Shared Resource (Charleston, SC) for
further processing.
2.3. Electrospray Ionization/Double MS Analysis. Following
extraction, SLs were separated by high-performance liq-
uid chromatography, introduced to electrospray ionization
source, and then analyzed by double MS using TSQ 7000
triple quadrupole mass spectrometer (Thermo-Fisher Scien-
tiﬁc) as described previously [32].
2.4. Mitochondrial Membrane Depolarization Measurement.
As we showed previously [36], the lipophilic cationic dye
JC-1 (5,5 ,6,6 -tetrachloro-1,1 3,3 -tetraethylbenzimidazo-
lylcarbocyanine iodide; Molecular Probes) was used to
determine mitochondrial membrane potential by ﬂow
cytometry. JC-1 forms aggregates in normal mitochondria
with a high negative membrane potential that emit a red
ﬂuorescence (590nm). In mitochondria with low membrane
potential (depolarized), the dye forms monomers in the
cytosol that emit a green ﬂuorescence (527nm) [37].
Following treatments, cells were collected, washed in
PBS, resuspended in JC-1-containing medium (2μMﬁ n a lJournal of Lipids 3
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Figure 2: LCL30 is taken up by SCCVII cells treated with LCL30
or (PDT+LCL30). (PDT+LCL30): following overnight exposure
to Pc 4 (250nM), cells were treated with LCL30 (1μM) for
2 hours, irradiated with red light (200mJ/cm2), and incubated
for additional 2 hours. For cells treated with LCL30 alone, the
incubation time was 4 hours. Following incubations, cells were
collected and processed for MS. The LCL30 levels are expressed as
actualvalues(pmol/mg)andareshownasaverage ±SEMfromfour
independent determinations.
concentration), and incubated at 37◦Cf o r1 5m i n u t e s .
The samples were centrifuged, resuspended in growth
medium, and analyzed by ﬂow cytometry using BD LSR
II ﬂow cytometer (BD Biosciences). As a positive control
for mitochondrial depolarization and apoptosis, cells were
treated with camptothecin (5μM) overnight and processed
for ﬂow cytometry.
2.5. Apoptosis Detection. As we showed previously [38], to
detect apoptosis, the exposure of phosphatidylserine in the
outer leaﬂet of the cell membrane was measured using
Annexin V, a protein which binds with high aﬃnity to
negatively charged phosphatidylserine in the presence of
calcium. As apoptosis progresses, cell membrane integrity is
lost, and this can be detected using DNA-binding ﬂuorescent
dye propidium iodide (PI, red ﬂuorescence). By attaching
Annexin V to the ﬂuorescein isothiocyanate (FITC; green
ﬂuorescence), one can discriminate between intact cells
(Annexin V negative, PI negative), early apoptotic (Annexin
V positive, PI negative), and late apoptotic or necrotic cells
(Annexin V positive, PI positive). The kit was purchased
from BD Pharmingen and the ﬂow cytometry protocol was
followed, as described by the manufacturer.
2.6. DEVDase (Caspase-3-Like) Activity Assay. As described
previously [34], the activity of the apoptotic marker DEVD-
ase was determined in cytosol by an assay based on the
enzyme’sabilitytocleavetheﬂuorogenicderivative7-amino-
4-methylcoumarin (AMC; Biomol) of the tetrapeptide
substrate N-acetyl-Asp-Glu-Val-Asp (DEVD). The released
ﬂuorescence of the cleaved DEVD substrate was measured in
Table 1: The eﬀect of LCL30, PDT, and PDT + LCL30 on the SL
proﬁle in SCCVII cells.
LCL30 PDT PDT + LCL30
Sphingolipids
a
C14-Cer 1.35 0.90 1.33
C16-Cer 1.02 1.13 1.53
C18-Cer 1.18 1.52 1.70
C18:1-Cer 1.12 1.19 1.48
C20-Cer 1.13 1.53 1.69
C20:1-Cer 1.64 1.65 2.06
C22-Cer 0.82 1.43 1.42
C22:1-Cer 1.23 1.11 1.41
C24-Cer 0.82 1.07 1.19
C24:1-Cer 1.09 1.09 1.37
C26-Cer 0.94 1.39 1.05
C26:1-Cer 0.77 1.46 1.46
C14-DHCer 0.71 1.60 1.64
C16-DHCer 0.72 1.52 1.22
C18-DHCer 0.67 1.25 1.00
C20-DHCer 0.96 1.30 1.40
C22-DHCer 0.97 1.90 1.70
C22:1-DHCer 1.20 1.73 2.28
C24-DHCer 0.67 1.16 1.14
C24:1-DHCer 0.99 1.36 1.51
DHSph 0.71 0.59 0.25
Sph 1.00 0.05 0.05
S1P 1.63 0.14 0.56
aThe data are shown as ratios compared to controls (untreated and Pc 4
alone). Signiﬁcant values at P<. 05 are shown in bold. C14-Cer, C14-
ceramide, and so forth; C14-DHCer, C14-dihydroceramide, and so forth;
DHSph, dihydrosphingosine; Sph, sphingosine.
F-2500 Hitachi spectroﬂuorometer (380nm excitation and
460nm emission).
2.7. Clonogenic Assay. Cell viability was assessed using
clonogenic assay. The protocol that we described previously
[38, 39] was modiﬁed using preplating approach, which
allows keeping the treatments in the medium during colony
formation. Following addition of Pc 4 or LCL30, cells were
seeded in the growth medium, preincubated overnight, and
irradiated. After eight days of growth at 37◦C, colonies (≥50
cells) were stained with crystal violet (0.1%) and counted.
Plating eﬃciency was 76% (n = 81).
2.8. Statistical Analysis. Statistical diﬀerences were deter-
mined using Student’s t-test (P<. 05).
3. Results and Discussion
3.1. LCL30 Is Taken up by SCCVII Cells. We showed rapid
uptake of LCL30 by MCF-7 cells [9]. Here, we determined
uptake of LCL30 by SCCVII cells using MS. Following a
four-hour incubation of cells with LCL30 (1μM), cellular
levels of LCL30 were 260 ± 4pmol/10 6 cells, corresponding4 Journal of Lipids
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Figure 3: The eﬀects of treatments on the SL proﬁle. (a)–(c) Total ceramides, DHceramides, and other SLs, respectively. The data are
expressed as fold changes, that is, ratios of treated versus controls (Pc 4 alone and untreated controls) and are shown as average ± SEM
from four independent determinations. For other details, refer to Figure 2 legend. The signiﬁcance (P<. 05) is shown as follows: ∗ indicates
the signiﬁcant diﬀerence between an individual treatment, LCL30 or PDT, and the combination (PDT+LCL30); ∼ indicates the signiﬁcant
diﬀerence between LCL30 and PDT. DHSph, dihydrosphingosine; Sph, sphingosine.
toapproximately5%oftheconcentrationapplied.AfterPDT
(250nM Pc 4 + 200mJ/cm2)+L C L 3 0( 1μM), cellular levels
of LCL30 were increased by 29% (Figure 2).The increasewas
marginally signiﬁcant (P<. 051).
3.2. PDT/LCL30 Is More Eﬀective Than Individual Treatments
in Raising Global Levels of Ceramides. We have already
demonstratedthatPDThassignatureeﬀectsontheSLproﬁle
in cancer cell lines and in vivo [21, 32, 39]. We [9]a n d
others [14] have also shown that LCL30 triggers changes in
endogenous ceramides and S1P in human cancer cell lines.
In the present study, we used MS to determine the eﬀects
of the combination, as well as of the individual treatments,
on the SL proﬁle in SCCVII cells. The eﬀects of treatments
on ceramides, individual and global, are shown in Table 1
and Figure 3(a). Only C20:1-ceramide was elevated after all
treatments. Globally, there was 1.29- and 1.47-fold increase
in ceramide levels after PDT and PDT/LCL30, respectively.
LCL30 had no eﬀect on total ceramides. The diﬀerences
between individual treatments, LCL30 or PDT, and the
combination, as well as between individual treatments
themselves, were signiﬁcant (P<. 05).
The eﬀects of treatments on the levels of dihydroce-
ramides (DHceramides), individual and global, are depicted
in Table 1 and Figure 3(b). Maximal increases were observed
forC22-andC22:1-DHceramideafterPDTandPDT/LCL30,
respectively. There was no signiﬁcant eﬀect of LCL30 on
total DHceramides. In contrast, PDT increased total DHce-
ramides 1.48-fold, and the eﬀect was maintained after the
combination.Journal of Lipids 5
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Figure 4: PDT, with or without LCL30, has no eﬀect on mitochondrial membrane potential or apoptosis. Following incubations, cells were
collected and processed for ﬂow cytometry. JC-1 and Annexin V/PI staining were used to detect mitochondrial membrane potential (a) and
apoptosis (b), respectively. See Section 2 for other details. (a) Percentage of cells with depolarized mitochondria is shown in lower right dot
plot. (b) Percentage of Annexin V (+)/PI (−) and Annexin V (+)/PI (+) is shown in lower right and upper right dot plot, respectively. The
representative data for PDT, with or without LCL30, from two independent experiments are shown.6 Journal of Lipids
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Figure 5: DEVDase activation is enhanced after (PDT+LCL30).
Following incubations (see Figure 2 legend), cells were collected,
cell lysates were prepared, and DEVDase activity was measured
using DEVD-AMC as the ﬂuorogenic substrate. The data are
expressed as fold changes, that is, ratios of treated versus untreated
c o n t r o l sa n da r es h o w na sa v e r a g e± SEM from four to six
independentdeterminations.Thesigniﬁcance(P<. 05)isshownby
an asterisk indicating signiﬁcant diﬀerence between an individual
treatment, LCL30 or PDT, and the combination (PDT+LCL30).
The eﬀects of treatments on other SLs are shown in
Table 1 and Figure 3(c). The levels of dihydrosphingosine
(DHsphingosine), a metabolic precursor of DHceramide,
were reduced by 29, 41, and 75% after LCL30, PDT, and
PDT/LCL30, respectively. The diﬀerences between treat-
ments were signiﬁcant (P<. 05). Thus, PDT/LCL30
was more eﬀective than individual treatments in reducing
DHsphingosine levels. Sphingosine levels were abolished
after PDT or the combination. LCL30 had no eﬀect on
sphingosine accumulation. In contrast, LCL30 triggered a
marked 1.63-fold rise in S1P levels. PDT reduced S1P levels
by 86%, and in combination with LCL30, by 44%.
3.3. PDT, with or without LCL30, Has No Eﬀect on
Mitochondrial Membrane Potential. We have shown that
PDT combined with C16-ceramide enhances mitochondrial
depolarization in Jurkat cells undergoing apoptosis [36].
Here, we tested whether PDT/LCL30 triggers the collapse
of mitochondrial potential in SCCVII cells. As depicted in
Figure 4(a), neither individual treatments nor the combina-
tionhadanyeﬀectonmitochondrialmembranepotential.In
contrast, overnight treatment with camptothecin (5μM) led
to the appearance of 63% cells with depolarized mitochon-
dria.
3.4. PDT, with or without LCL30, Has No Eﬀect on Apoptosis.
PDT is a potent apoptotic inducer [40]. Surprisingly, in
the presence of PDT, with or without LCL30, no apoptosis
was detected in SCCVII cells using either Annexin V/PI
staining (Figure 4(b)) or TUNEL assay (not shown). How-
ever, overnight treatment with camptothecin (5μM) led to
the appearance of 9% and 75% cells that were Annexin V
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Figure 6: Overall cell killing is promoted after (PDT+LCL30).
Following the addition of Pc 4 or LCL30, cells were seeded in the
growth medium, preincubated overnight, and irradiated with red
light (200mJ/cm2). After eight days of growth at 37◦C, colonies
(≥50 cells) were stained with crystal violet (0.1%) and counted.
The data are expressed as the percentage of killing and are shown
as average ± SEM from six to 26 independent determinations.
(a) Dose-dependent increase in cell killing after LCL30. The
signiﬁcance (P<. 05) is shown as follows: ∗ indicates the signiﬁcant
diﬀerence between lower doses (0.1 or 1μM) and the highest LCL
30 dose (5μM); ∼ indicates the signiﬁcant diﬀerence between 0.1
and 1μM LCL30. (b) Total cell killing is augmented after (PDT +
1μM LCL30). The signiﬁcance (P<. 05) is shown as follows: ∗
indicatesthesigniﬁcantdiﬀerencebetweenanindividualtreatment,
LCL30orPDT,andthecombination(PDT+LCL30); ∼indicatesthe
signiﬁcant diﬀerence between LCL30 and PDT.
(+)/PI (−) and Annexin V (+)/PI (+), respectively. Thus,
unlike other treatments, camptothecin triggers early and late
apoptosis/necrosis.
3.5. PDT/LCL30 Enhances DEVDase Activation. Although
LCL30 was reported not to induce apoptosis [14], PDT is
an eﬀective apoptotic inducer [41]. We used DEVDase assay
to assess the activity of caspase-3 as an apoptotic marker.Journal of Lipids 7
DEVDase was activated 1.47- and 1.95-fold after LCL30
and PDT, respectively (Figure 5). After treatment of SCCVII
cells with the combination, a 5.68-fold increase in DEVDase
activity was recorded. Therefore, the combined treatment
augments the enzyme activity.
Previously, we showed that enhanced ceramide accumu-
lation is associated with increased activation of DEVDase
after PDT [32, 35]. We also showed that DEVDase activation
is accompanied by mitochondrial depolarization and/or
apoptosis post-PDT [33–36, 42, 43]. The present study
shows DEVDase activation in the absence of mitochondrial
depolarization and apoptosis after PDT, with or without
LCL30. Caspases, including caspase-3, have been associated
with nonapoptotic functions, for example, survival [44–46].
Curiously, there was positive correlation between DEVDase
activation and the levels of prosurvival S1P after LCL30.
In addition, there was negative correlation between the
proapoptotic DHsphingosine [33] and DEVDase activation.
The levels of proapoptotic sphingosine [47] were abolished
after PDT or the combination with concomitant activation
of DEVDase. The role of DEVDase activation in the absence
of apoptosis in response to PDT, with or without LCL30,
remains to be established.
3.6. PDT/LCL30 Augments Cell Killing. To determine the
eﬀect of LCL30 on overall cell killing, clonogenic assay was
employed. As shown in Figure 6(a), treatment of SCCVII
cells with 0.1, 1 and 5μM LCL30 led to 7.8, 21.5 and 97.7%
cell killing, respectively. The diﬀerences between each dose
were signiﬁcant (P<. 05), supporting a dose-dependent cell
killing after LCL30.
To test for potential enhancement of cell killing by the
combination, LDs < 30 were chosen for each treatment.
When SCCVII cells were treated with LCL30 (1μM) and
PDT (250nM Pc 4 + 200mJ/cm2), 69.8% of the overall cell
killing was observed (Figure 6(b)). The combination led to
cell killing that was greater than that by each treatment alone
(P<. 05).
Taken together, the present study demonstrates for the
ﬁrst time that (i) LCL30 is taken up by SCCVII cells; (ii) cel-
lular total ceramides are enhanced after PDT/LCL30; (iii) the
activity of DEVDase is upregulated in the absence of mito-
chondrial depolarization and apoptosis post-PDT/LCL30;
(iv)totalcellkillingisaugmentedafterthecombination.Our
ﬁndings warrant the use of other apoptotic markers besides
DEVDase to verify the triggering of apoptosis, and in vivo
testing of PDT/LCL30 in view of translational potential of
the combination.
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